Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclosporin for steroid-dependent asthma.

A Szczeklik1, E Nizankowska, R Dworski

  • 1Department of Medicine, Copernicus Academy of Medicine, Cracow, Poland.

Allergy
|May 1, 1991
PubMed
Summary

Low-dose cyclosporine may help some patients with severe, steroid-dependent asthma reduce their oral prednisone dosage. While six patients improved, others could not reduce steroid doses, indicating variable patient response.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Induced sputum supernatant bioactive lipid mediators can identify subtypes of asthma.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2015
Same author

Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs.

Allergy·2013
Same author

Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs.

The Journal of allergy and clinical immunology·2012
Same author

12-hydroxy-eicosatetraenoic acid (12-HETE): a biomarker of Churg-Strauss syndrome.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2012
Same author

Exhaled Eicosanoids following Bronchial Aspirin Challenge in Asthma Patients with and without Aspirin Hypersensitivity: The Pilot Study.

Journal of allergy·2012
Same author

Serum tryptase level is a better predictor of systemic side effects than prostaglandin D2 metabolites during venom immunotherapy in children.

Journal of investigational allergology & clinical immunology·2011

Area of Science:

  • Immunology
  • Pulmonology
  • Pharmacology

Background:

  • Severe bronchial asthma often requires long-term systemic steroid therapy.
  • Systemic steroids can lead to significant side effects with prolonged use.
  • Identifying steroid-sparing agents is crucial for managing severe asthma.

Purpose of the Study:

  • To evaluate the efficacy of low-dose cyclosporine in reducing systemic steroid requirements in patients with severe bronchial asthma.
  • To assess the impact of cyclosporine on asthma symptom control and exacerbations.

Main Methods:

  • A prospective study involving 12 adult patients with severe, steroid-dependent asthma.
  • Standardization of background asthma therapies including inhaled beclomethasone, aminophylline, and salbutamol.

Related Experiment Videos

  • Treatment with low-dose cyclosporine (average trough levels 105 ng/ml) for 9 months, with attempts to reduce oral prednisone.

    • Main Results:

    • Six out of 12 patients successfully reduced their daily prednisone dose from a mean of 30 mg to 11 mg.
    • Significant improvements in daily symptom scores and peak expiratory flows were observed in responders.
    • Reduced asthma exacerbations were noted in patients who could taper steroids.
    • Six patients did not tolerate steroid dose reduction, and cyclosporine was discontinued.

    Conclusions:

    • Low-dose cyclosporine shows potential as an adjunctive therapy for some patients with steroid-dependent asthma.
    • Patient response to cyclosporine appears variable, necessitating further investigation.
    • Cyclosporine may offer a steroid-sparing benefit in a subset of severe asthma patients.